Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02208063 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
A Phase 3 study, sponsored by Cumberland Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
NCT02208063: Clinical Trial Phase 3 study, sponsored by Cumberland Pharmaceuticals.
NCT02208063 is a Phase 3 study that was terminated before completion, run by Cumberland Pharmaceuticals. The registered enrollment target is 121 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02208063, a Phase 3 study, was terminated before completion, sponsored by Cumberland Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA right-sided infective endocarditis (SA-RIE).
Primary Outcome
The efficacy endpoint of clinical outcome of cure at the test of cure (TOC) was determined by subjects who meet all of the following criteria, as determined by the investigator and adjudicated by the blinded independent efficacy adjudication committee (IEAC). 1. Alive at TOC 2. Resolution of all clinical signed and symptoms of the Staphylococcus aureus (S. aureus) infection at TOC 3. No evidence of microbiological persistence of relapse 4. No new foci of metastatic S. aureus infection after Day
Interventions
- DRUG Vancomycin
- DRUG Cefazolin
- DRUG Daptomycin
- DRUG Telavancin
- DRUG Synthetic penicillin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-04-12 |
| Phase | Phase 3 |
Why NCT02208063 stopped before completion
NCT02208063 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 5 interventions - of which Vancomycin is the first listed.
NCT02208063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02208063 about?
NCT02208063 is a clinical study titled "A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial". This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA ri...
What is the current status of trial NCT02208063?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2014-12. Estimated completion is 2018-04-12.
What interventions are being tested in trial NCT02208063?
The interventions under investigation include: Vancomycin (DRUG), Cefazolin (DRUG), Daptomycin (DRUG), Telavancin (DRUG), Synthetic penicillin (DRUG).
Who is sponsoring clinical trial NCT02208063?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02208063's enrollment target sits among peer trials
121 1619th of 2000 higher than 382 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia